Results 91 to 100 of about 57,632 (243)

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

Arthritis &Rheumatology, EarlyView.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis, Denis Mongin, Denis Choquette, Louis Coupal, Catalin Codreanu, Florenzo Iannone, Roberto Caporali, Tore K. Kvien, Sella Provan, Ruth Fritsch‐Stork, Dan Nordström, Nina Trokovic, Karel Pavelka, Jakub Závada, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Irini Flouri, Céline Lamacchia, Michele Iudici, Delphine Courvoisier, Kim Lauper, Axel Finckh   +22 more
wiley   +1 more source

Clinical Images: Subcutaneous panniculitis‐like T cell lymphoma

Arthritis &Rheumatology, EarlyView.
S Chambers, CN Myrdal, VP Werth
wiley   +1 more source

The American College of Rheumatology Updated Recommended Methods for Development of Disease Classification and Response Criteria

Arthritis &Rheumatology, EarlyView.
Disease classification criteria and response criteria are important tools in the conduct of observational studies and clinical trials for rheumatic diseases. This paper updates methodologic guidance for classification and response criteria funded, developed and/or endorsed by the American College of Rheumatology (ACR), incorporating contemporary ...
Sindhu R. Johnson, Tuhina Neogi, Amy S. Turner, Jaime Guzman, Zahi Touma   +4 more
wiley   +1 more source

A Pragmatic Trial of a Shared Decision‐Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ‐SAFE Study

Arthritis &Rheumatology, EarlyView.
Objective Hydroxychloroquine (HCQ) nonadherence in systemic lupus erythematosus (SLE) stemming from decision complexities can be improved with shared decision‐making (SDM) tools clarifying benefits and harms. This study aimed to develop and evaluate HCQ‐SAFE, a pictogram‐based SDM tool during SLE visits.
Caroline Packee, Jay J. Patel, Jessica Kent, Betty Chewning, Sancia Ferguson, Patricia Tellez‐Giron, David Gazeley, Christie M. Bartels, Shivani Garg   +8 more
wiley   +1 more source

Hydroxychloroquine and Chloroquine

Clinical Infectious Diseases, 2020
openaire   +2 more sources

Autoreactivity vs autoimmunity: characteristics of autoantigen‐specific CD4 T‐cells in rheumatoid arthritis and health.

Arthritis &Rheumatology, Accepted Article.
Background CD4 T cells specific for citrullinated (cit)‐peptides are key players in RA immunopathogenesis. Characterising these cells and identifying features of healthy and RA‐associated autoreactivity will provide valuable insight into disease mechanisms and form the basis of immune state biomarkers to facilitate the next generation of RA treatments.
James A. Stanway, Daniel Peters, Helen Waller, Jeremy Lakey, Henrique De Paula Lemos, Kristian Williams, Abbie Degnan, Julie Diboll, Abdul Mannan Baru, David Tough, Arthur G. Pratt, Catharien M.U. Hilkens, Amy E. Anderson, John D. Isaacs   +13 more
wiley   +1 more source

Increased plasma microbial tDR‐1 in at‐risk individuals is associated with decreased conversion to clinical rheumatoid arthritis and reduces an in vitro macrophage type 1 interferon response

Arthritis &Rheumatology, Accepted Article.
Background Microbial small RNAs (sRNAs) can regulate human genes. Higher plasma concentrations of microbial tRNA‐derived RNA‐1 (tDR‐1) were previously associated with lower rheumatoid arthritis (RA) disease activity. This study examined whether tDR‐1 concentrations differ in anti‐cyclic citrullinated peptide‐3 positive (CCP3+) at‐risk individuals (ARI)
Anastasiia Phothisane, Tulsi K Joishy, Carolina Ramirez‐Becerra, Qiong Wu, Jennifer Seifert, Marie L Feser, Jill M Norris, M Kristen Demoruelle, LauraKay Moss, Kevin D Deane, V Michael Holers, Michelle J Ormseth   +11 more
wiley   +1 more source

The prophylactic effect of hydroxychloroquine on the severity of COVID-19 infection in an asymptomatic population: A randomized clinical trial

Social Determinants of Health
Background: Laboratory and observational data suggest that hydroxychloroquine (HCQ) has biological activity against SARS-CoV-2, potentially permitting its use for disease prevention.
Arezoo Chouhdari
doaj   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source